Coffee with Samso Episode 206 is about how we understand and interact with AI. This episode of Coffee with Samso is asking if we really know what Artificial Intelligence is about ? Are we just taking it for granted the simplicity of the word AI and is it sufficient to just take what people say about about what AI will do for or to us in the coming years.

Mesoblast Limited (ASX: MSB | Nasdaq: MESO) has taken a critical step toward commercialising its lead cardiac product candidate, Revascor® (rexlemestrocel-L), with formal alignment reached with the United States Food and Drug Administration (FDA) on the key requirements for filing a Biologics License Application (BLA) in the treatment of ischemic heart failure with reduced ejection fraction (HFrEF) and inflammation.

NeuroScientific Biopharmaceuticals Ltd (ASX: NSB) has taken a major strategic step by acquiring StemSmart™, a globally patented and clinically validated stem cell platform. This acquisition adds a powerful, next-generation therapeutic capability to the company’s focus on neuroimmune and inflammatory diseases.

30 June 2025 – Lightning Minerals Ltd (ASX: L1M) has announced a transformational acquisition of two advanced brownfields projects targeting gold and copper in Queensland  (Mt Turner Projects) and New South Wales (Lachlan Fold Copper Porphyry Project). The acquisition of Lotus Minerals Pty Ltd significantly strengthens the Company’s portfolio and introduces immediate drill targets in some of Australia’s most mineral-endowed regions.

OpenLearning Limited (ASX: OLL) has secured two strategic SaaS agreements in quick succession, expanding its reach in both Southeast Asia and Australia. The first, a A$495,000 deal with CE-Logic Inc. in the Philippines and a 5-year A$155,000 agreement with the Education Centre of Australia. Together, these wins underscore OpenLearning’s growing momentum across key education markets.

Wide Open Agriculture Ltd (ASX: WOA) has announced a major technical milestone with the successful completion of a commercial-scale manufacturing trial of its proprietary lupin protein isolate process (BP80F), conducted in the United States. Samso has previously covered WOA's journey in lupin-based innovation, and this latest update continues that narrative of disciplined progress and technical refinement.

RareX Limited (ASX: REE) has delivered another round of eye-catching assay results that significantly strengthen its position as the developer of one of Australia's most advanced and highest-grade gallium deposits at the Cummins Range Project (Figure 1). The latest update, announced on 24 June 2025, showcases high-grade gallium re-assays from Cummins Range and builds upon an already compelling narrative that began with RareX’s March 2025 discovery announcement.

In March 2025, Cyprium Metals Ltd (ASX: CYM) presented a clear vision to the market—a strategy built on speed, simplicity, and a low-capex restart of the Nifty Copper Complex (Figure 1). The March investor presentation positioned Nifty as a rare brownfield asset with infrastructure already in place, permits largely secured, and over 720kt of copper historically produced.

Zeotech Limited (ASX: ZEO) has released a Preliminary Feasibility Study (PFS) for its AusPozz™ Project, confirming the strong technical and economic potential of Australia’s first metakaolin manufacturing facility for the production of low-carbon concrete additives. The study marks a major milestone for Zeotech’s ambition to support Australia’s decarbonisation efforts and transform the construction materials landscape.

AIC Mines Limited (ASX: A1M) has reached a major funding milestone with the successful completion of a $55 million Placement and the signing of a US$40 million Prepayment Facility and Offtake Agreement with Trafigura. These capital moves form a cornerstone of the company’s strategy to expand the Eloise Processing Plant and develop the Jericho Copper Mine, paving the way for a significant lift in copper output.

West Cobar Metals Limited (ASX: WC1) has concluded a focused reverse circulation (RC) drilling program across its wholly owned Fraser Range Project in southern Western Australia. Situated 120 km north-east of Esperance, this region sits within the Biranup Zone—an important structural corridor adjacent to the Fraser Zone, host of the Nova-Bollinger nickel-copper deposit.

Amplia Therapeutics Limited (ASX: ATX) is entering a compelling phase in its clinical journey, as recent announcements reinforce the growing potential of its lead compound, narmafotinib (AMP945), in the fight against advanced pancreatic cancer(Figure 1). With news of two rare and confirmed complete responses emerging from the ongoing ACCENT trial, investors have reason to take notice. These outcomes are not only clinically remarkable—they may signal a turning point in one of